The OPTIN Contact Bulletin

 

New Projects in

INFORMATION BASED MEDICINE

from Israel

No 09 - December 2002

                                            http://www.optin.nl/

 

 

Projects:

1.        GenMed – a Tool for Personalized Medicine

2.        Telemedicine - Transtelephonic Monitoring Systems

3.        Integrated Telemedicine-Based Home Care

4.        Advanced Telemedicine solutions

5.        Medical Image Management Systems

6.        Transtelephonic Diagnostic Equipmen

7.        Sustained Release Dosage Forms of Low-Molecular Weight Antioxidants

8.        Treatment of Cancer and/or Lipid Storage Diseases by Novel, Synthetic Compounds that Modify Sphingolipid Metabolism

9.        Possible Applications for DNA Oligonucleotidesm Synthesized Directly On Glass Support(Biotech / Diagnostic)

 

 

 

In the News:

1.     IBM is active in the field of Information Based Medicine

2.     Compugen Announces Licensing of its Z4000 System for Proteomic Research to Organon and Procter & Gamble

3.     Israeli-developed gene test for diabetics

4.     Commission calls for experts to evaluate scientific projects

 

 

 

 

For more information about Life Sciences in Israel and in The Netherlands see the OPTIN site: http://www.optin.nl/ your portal to Israeli and Dutch biotechnology.

For background and contact information on the listed projects  please mail to: mailto:e.guetta@optin.nl  or call:  +31-(0)70-3643260.

Sponsors:

DSM Venturing

IBM Life Sciences

Tel Aviv University

The Embassy of Israel

CIDI

Matimop

Nmedica

Contributors:

Tel Aviv University/ Ramot

The Hebrew University/ Yissum

Weizmann Institute/ Yeda

Bar Ilan University

Ben-Gurion University

Hadasit

Technion

Matimop

 

 

Events:

BIO-TECH ISRAEL 2003

13-15 May 2003, Tel Aviv,  Israel

AGRITECH 2003 EXHIBITION

15-18 September 2003, Tel Aviv,  Israel

New Innovative Technologies in Medicine from Israel and The Netherlands

September 2003, The Hague, The Netherlands

 

 

Coming up in January bulletin:

New projects in “Oncology and Cancer Therapy”

 

For extra information and benefits specifically for sponsors, please contact OPTIN.